Bullous disorders associated with anti–PD‐1 and anti–PD‐L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy

[1]  L. Geskin,et al.  A review of bullous pemphigoid associated with PD‐1 and PD‐L1 inhibitors , 2018, International journal of dermatology.

[2]  B. Kwong,et al.  Localized bullous pemphigoid in a melanoma patient with dual exposure to PD-1 checkpoint inhibition and radiation therapy , 2017, JAAD case reports.

[3]  S. Granter,et al.  Rituximab Treatment of Nivolumab-Induced Bullous Pemphigoid. , 2017, JAMA dermatology.

[4]  J. Wargo,et al.  Diverse types of dermatologic toxicities from immune checkpoint blockade therapy , 2017, Journal of cutaneous pathology.

[5]  M. Tomayko,et al.  Development of bullous pemphigoid during nivolumab therapy , 2016, JAAD case reports.

[6]  S. Gettinger,et al.  Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy. , 2016, JAMA dermatology.

[7]  R. Hui,et al.  PD-1 inhibitors induced bullous lichen planus-like reactions: a rare presentation and report of three cases. , 2016, Melanoma research.

[8]  J. Mazières,et al.  Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies , 2016, Current opinion in oncology.

[9]  K. Byth,et al.  Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort. , 2016, Journal of the American Academy of Dermatology.

[10]  J. Wolchok,et al.  Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1 , 2016, Cancer Immunology Research.

[11]  J. Chen,et al.  CD47: a potential immunotherapy target for eliminating cancer cells , 2016, Clinical and Translational Oncology.

[12]  G. Gibney,et al.  Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes , 2015, Clinical Cancer Research.

[13]  T. Krenács,et al.  Collagen XVII is expressed in malignant but not in benign melanocytic tumors and it can mediate antibody induced melanoma apoptosis , 2012, Histochemistry and Cell Biology.

[14]  B. Molnár,et al.  Immunophenotypic Profiling of Nonsmall Cell Lung Cancer Progression Using the Tissue Microarray Approach , 2007, Applied immunohistochemistry & molecular morphology : AIMM.